Cardiff Oncology (CRDF) Stock Price, News & Analysis

Company Overview

Cardiff Oncology is a clinical-stage biotechnology company focused on developing personalized combination therapies for the treatment of cancer. By leveraging its proprietary OncoSignature platform, the company integrates genomic, transcriptomic and proteomic data to predict synergistic interactions between immuno-oncology agents and targeted drugs. Cardiff Oncology’s approach aims to move beyond single-agent therapies by identifying optimal regimens that address the complexity and heterogeneity of tumor biology.

The company’s pipeline includes multiple combination therapy candidates in clinical trials for various solid tumors and hematological malignancies. Its lead programs explore the use of checkpoint inhibitors in tandem with small-molecule inhibitors and monoclonal antibodies, with early data demonstrating potential benefits in tumor response rates. Cardiff Oncology also collaborates with academic medical centers and contract research organizations to accelerate the design and execution of its clinical studies.

Founded in 2012 and headquartered in San Diego, California, Cardiff Oncology has expanded its research and development operations across the United States. Since inception, the company has built a multidisciplinary team of scientists, clinicians and data analysts dedicated to precision oncology. In recent years, Cardiff Oncology has entered strategic partnerships to enhance its translational research capabilities, drawing on expertise in bioinformatics and molecular diagnostics.

Cardiff Oncology is led by an executive team with extensive experience in oncology drug development, regulatory affairs and commercial strategy. The company’s leadership includes veterans from major pharmaceutical and biotechnology firms, underscoring its commitment to advancing innovative cancer therapies. With a focus on personalized medicine and data-driven insights, Cardiff Oncology seeks to deliver new combination treatments that improve outcomes for patients with difficult-to-treat cancers.

Key Stats

• Today's Range: $3.75 to $3.98
• 50-Day Range: $2.67 to $4.45
• 52-Week Range: $2.01 to $5.64
• Volume: 922,591 shs
• Average Volume: 1.24 million shs
• Market Capitalization: $259.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.70
• Consensus Rating: Moderate Buy

Cardiff Oncology Stock Analysis - MarketRank™

Cardiff Oncology scored higher than 19% of companies evaluated by MarketBeat, and ranked 839th out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cardiff Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Cardiff Oncology has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cardiff Oncology are expected to grow in the coming year, from ($0.99) to ($0.94) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cardiff Oncology is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cardiff Oncology is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cardiff Oncology has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

29.93% of the float of Cardiff Oncology has been sold short.

Short Interest Ratio / Days to Cover

Cardiff Oncology has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Cardiff Oncology has recently increased by 6.30%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cardiff Oncology does not currently pay a dividend.

Dividend Growth

Cardiff Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

29.93% of the float of Cardiff Oncology has been sold short.

Short Interest Ratio / Days to Cover

Cardiff Oncology has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Cardiff Oncology has recently increased by 6.30%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Cardiff Oncology this week, compared to 1 article on an average week.

Search Interest

Only 3 people have searched for CRDF on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Cardiff Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cardiff Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.70% of the stock of Cardiff Oncology is held by insiders.

Percentage Held by Institutions

Only 16.29% of the stock of Cardiff Oncology is held by institutions.

CRDF Stock Analysis - Frequently Asked Questions

How have CRDF shares performed this year?

Cardiff Oncology's stock was trading at $4.34 at the beginning of the year. Since then, CRDF shares have decreased by 11.9% and is now trading at $3.8240.

How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:CRDF) issued its earnings results on Thursday, May, 8th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.01. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.09 million. Cardiff Oncology had a negative trailing twelve-month return on equity of 76.45% and a negative net margin of 8,308.50%.

Who are Cardiff Oncology's major shareholders?

Cardiff Oncology's top institutional investors include SteelPeak Wealth LLC (0.03%) and Baader Bank Aktiengesellschaft (0.02%). Insiders that own company stock include Gary W Pace, Lale White, James E Levine and Mark Erlander.
View institutional ownership trends.

How do I buy shares of Cardiff Oncology?

Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Digital Turbine (APPS), Meta Platforms (META) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/23/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRDF
• CIK: 1213037
• Web: cardiffoncology.com
• Phone: (858) 952-7570
• Fax: N/A
• Employees: 20
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Cardiff Oncology: $11.70
• High Price Target: $19.00
• Low Price Target: $3.50
• Potential Upside/Downside: +200.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.43 million
• Net Margins: -8,308.50%
• Pretax Margin: -8,308.50%
• Return on Equity: -76.45%
• Return on Assets: -62.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.22
• Quick Ratio: 6.22

Sales & Book Value

• Annual Sales: $587 thousand
• Price / Sales: 441.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.86 per share
• Price / Book: 2.09

Miscellaneous

• Outstanding Shares: 66,526,000
• Free Float: 61,403,000
• Market Cap: $259.12 million
• Optionable: Optionable
• Beta: 1.52